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Background: Anti-integrin antibodies are effective therapies for Crohn’s disease (CD) and ulcerative colitis (UC). However, these drugs carry theoretical risks of opportunistic infection and malignancy. No systematic review and meta-analysis has examined this issue specifically. 
Aims: We pooled data from all placebo-controlled studies to estimate risk of opportunistic infection or malignancy with anti-integrin antibodies. 
Methods: MEDLINE, EMBASE, and the Cochrane central register of controlled trials were searched (through to December 2014). Randomised placebo-controlled trials of anti-integrin antibodies in adults with active or quiescent CD or UC were eligible. Dichotomous data were pooled to obtain a relative risk (RR) of opportunistic infection or malignancy, with 95% confidence intervals (CIs).
Results: The search strategy identified 1,579 citations, 12 of which were eligible (four trials of natalizumab, six of vedolizumab, and two of etrolizumab). The RR of developing an opportunistic infection was not significantly higher with non-gut specific (2.34; 95% CI 0.05-108.72) or gut specific anti-integrin antibodies (1.55; 95% CI 0.16-14.83). The RR was generally higher in trials of non-gut specific anti-integrin antibodies with duration of therapy ≥52 weeks (RR = 15.00; 95% CI 0.86 to 261), but remained non-significant. The RR of malignancy was not elevated with non-gut specific (1.57; 95% CI 0.19-12.74) or gut specific anti-integrin antibodies (0.78; 95% CI 0.15-4.02).
Conclusions: Absolute numbers of opportunistic infections were higher with anti-integrin antibodies, but this difference was not statistically significant. There was no increased risk of malignancy detected. Long-term data in large prospective cohorts are needed to further assess this issue. 
INTRODUCTION
Crohn’s disease (CD) and ulcerative colitis (UC) are chronic inflammatory disorders of the gastrointestinal tract of unknown aetiology. ,  Unless effective medical therapy is instituted, these diseases follow a relapsing and remitting course, with flares of disease activity characterised by abdominal pain, diarrhoea, and rectal bleeding. However, a significant proportion of patients with both CD and UC either do not achieve a sustained remission of disease activity with, or lose response to, conventional therapies, such as 5-aminosalicylates or immunosuppressants.  ADDIN EN.CITE 3-9 
Anti-tumour necrosis factor-α (TNFα) drugs have changed the way we treat inflammatory bowel disease (IBD) refractory to standard medications. However, these drugs are associated with an increased risk of opportunistic infection.  HYPERLINK \l "_ENREF_10" \o "Ford, 2013 #120"  ADDIN EN.CITE <EndNote><Cite><Author>Ford</Author><Year>2013</Year><RecNum>120</RecNum><DisplayText><style face="superscript">10</style></DisplayText><record><rec-number>120</rec-number><foreign-keys><key app="EN" db-id="wwaffps2axz0tyewa52xw9rofzd5z59xe5rx">120</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Ford, A. C.</author><author>Peyrin-Biroulet, L.</author></authors></contributors><titles><title>Opportunistic infections with anti-tumor necrosis factor-a therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials</title><secondary-title>Am J Gastroenterol</secondary-title></titles><periodical><full-title>Am J Gastroenterol</full-title></periodical><pages>1268-1276</pages><volume>108</volume><reprint-edition>IN FILE</reprint-edition><dates><year>2013</year></dates><urls></urls></record></Cite></EndNote>10 With the exception of skin cancer, anti-TNFα therapy by itself does not seem to increase malignancy risk in IBD.  HYPERLINK \l "_ENREF_11" \o "Williams, 2014 #495"  ADDIN EN.CITE <EndNote><Cite><Author>Williams</Author><Year>2014</Year><RecNum>495</RecNum><DisplayText><style face="superscript">11</style></DisplayText><record><rec-number>495</rec-number><foreign-keys><key app="EN" db-id="wwaffps2axz0tyewa52xw9rofzd5z59xe5rx">495</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Williams, C. J.</author><author>Peyrin-Biroulet, L.</author><author>Ford, A. C.</author></authors></contributors><titles><title>Systematic review with meta-analysis: malignancies with anti-tumour necrosis factor-alpha therapy in inflammatory bowel disease</title><secondary-title>Aliment Pharmacol Ther</secondary-title></titles><periodical><full-title>Aliment Pharmacol Ther</full-title></periodical><pages>447-58</pages><volume>39</volume><number>5</number><dates><year>2014</year></dates><isbn>1365-2036 (Electronic)&#xD;0269-2813 (Linking)</isbn><work-type>Meta-Analysis&#xD;Review</work-type><urls></urls></record></Cite></EndNote>11 Due to the well-known limitations of anti-TNFα agents, including safety concerns, tolerability, primary non-response, and secondary loss of response, there is a significant unmet need for novel agents for the treatment of IBD. 
One factor in the pathogenesis of IBD is the migration of lymphocytes in to the inflamed intestinal mucosa. This is mediated by interactions between mucosal adhesion molecules on the intestinal vasculature, which are upregulated at sites of active inflammation, and glycoproteins on the surface of lymphocytes, including the α4β1 and α4β7 integrins.  ADDIN EN.CITE ,  HYPERLINK \l "_ENREF_13" \o "Arihiro, 2002 #493"  Drugs that inhibit this interaction, by selectively binding to these integrins, have been tested in both CD and UC, and are more effective than placebo for both the induction and maintenance of remission.  ADDIN EN.CITE 14-18  
However, one such drug, natalizumab, has been associated with the development of JC virus-induced progressive multifocal leukoencephelopathy.  HYPERLINK \l "_ENREF_19" \o "Van Assche, 2005 #496"  ADDIN EN.CITE <EndNote><Cite><Author>Van Assche</Author><Year>2005</Year><RecNum>496</RecNum><DisplayText><style face="superscript">19</style></DisplayText><record><rec-number>496</rec-number><foreign-keys><key app="EN" db-id="wwaffps2axz0tyewa52xw9rofzd5z59xe5rx">496</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Van Assche, G.</author><author>Van Ranst, M.</author><author>Sciot, R.</author><author>Dubois, B.</author><author>Vermeire, S.</author><author>Noman, M.</author><author>Verbeeck, J.</author><author>Geboes, K.</author><author>Robberecht, W.</author><author>Rutgeerts, P.</author></authors></contributors><titles><title>Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn&apos;s disease</title><secondary-title>N Engl J Med</secondary-title></titles><periodical><full-title>N Engl J Med</full-title></periodical><pages>362-8</pages><volume>353</volume><number>4</number><dates><year>2005</year></dates><isbn>1533-4406 (Electronic)&#xD;0028-4793 (Linking)</isbn><work-type>Case Reports</work-type><urls></urls></record></Cite></EndNote>19 This has led to the development of newer drugs acting more selectively on the α4β7 integrin, such as vedolizumab, etrolizumab, and AMG 181 which are gut specific, and are therefore less likely to cause adverse neurological events.  An increased risk of other infections, such as tuberculosis, or malignancy may still be an issue but, as these types of adverse events are rare, individual RCTs are not powered to assess this. In addition, previous meta-analyses of these agents in IBD have not focussed on this issue.  ADDIN EN.CITE , ,  





Search Strategy and Study Selection
We performed a search of the medical literature using MEDLINE (1946 to December 2014), EMBASE and EMBASE Classic (1947 to December 2014), the Cochrane central register of controlled trials, and the Cochrane IBD Group Specialised Trials Register. Randomised controlled trials that examined the effect of anti-integrin antibodies in adult patients (>90% of participants over the age of 16 years) with active or quiescent IBD were eligible for inclusion in the meta-analysis (Box 1). The first period of cross-over RCTs were also eligible for inclusion. Patients in the control arms were required to receive placebo. Duration of anti-integrin antibody therapy had to be at least 2 weeks. Trials that used a single infusion or injection of anti-integrin antibody were ineligible. Where an induction of remission trial continued to study maintenance of remission in the same group of patients, we only included the maintenance of remission study, in order not to double count participants. Studies had to report absolute numbers of opportunistic infections or malignancies with active therapy, compared with placebo, during the randomised double-blind treatment period of the trial. First and senior authors of studies were contacted to provide additional information on individual trials where required.
The literature search used the following terms: Crohn disease, inflammatory bowel disease, colitis, ileitis, or ulcerative colitis (both as medical subject headings (MeSH) and free text terms), or Crohn$ disease and regional enteritis (as free text terms). These were combined using the set operator AND with studies identified with the following free text terms: natalizumab, antegren, tysabri, vedolizumab, MLN02, MLN0002, etrolizumab, anti-integrin antibodies, anti integrin antibodies, anti-adhesion molecules, anti adhesion molecules, or AMG 181.
There were no language restrictions. Abstracts of the papers identified by the initial search were evaluated by the lead investigator for appropriateness to the study question, and all potentially relevant papers were obtained and evaluated in detail. Foreign language papers were translated where necessary. Abstract books of conference proceedings from the British Society of Gastroenterology, Digestive Diseases Week, United European Gastroenterology Week, and the European Crohn’s and Colitis Organisation between 2002 and 2014 were hand-searched to identify other potentially eligible studies. The bibliographies of all identified relevant studies were used to perform a recursive search of the literature. Experts in the field were contacted to try to identify other unpublished studies. Articles were assessed independently by two investigators using pre-designed eligibility forms, according to the pre-defined eligibility criteria. Any disagreement between investigators was resolved by discussion. 

Outcome Assessment
	The primary outcome assessed was the occurrence of any opportunistic infection or malignancy with non-gut specific (natalizumab targeting integrins containing the α4 subunit) or gut specific (vedolizumab targeting α4β7, and etrolizumab targeting α4β7 and αEβ7) anti-integrin antibodies, compared with placebo. Opportunistic infections of interest, as we have described previously,  HYPERLINK \l "_ENREF_10" \o "Ford, 2013 #120"  ADDIN EN.CITE <EndNote><Cite><Author>Ford</Author><Year>2013</Year><RecNum>120</RecNum><DisplayText><style face="superscript">10</style></DisplayText><record><rec-number>120</rec-number><foreign-keys><key app="EN" db-id="wwaffps2axz0tyewa52xw9rofzd5z59xe5rx">120</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Ford, A. C.</author><author>Peyrin-Biroulet, L.</author></authors></contributors><titles><title>Opportunistic infections with anti-tumor necrosis factor-a therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials</title><secondary-title>Am J Gastroenterol</secondary-title></titles><periodical><full-title>Am J Gastroenterol</full-title></periodical><pages>1268-1276</pages><volume>108</volume><reprint-edition>IN FILE</reprint-edition><dates><year>2013</year></dates><urls></urls></record></Cite></EndNote>10 included Mycobacterium tuberculosis, JC virus, oral or oesophageal candidiasis, varicella-zoster virus infection, herpes zoster infection, cytomegalovirus or Epstein-Barr virus infection, Nocardia infection, Pneumocytsis jirovecii infection, Histoplasma capsulatum infection, Mycobacterium avium complex infection, herpes simplex infection, or other unspecified opportunistic infections. Data concerning the occurrence of any type of malignancy were considered relevant. 

Data Extraction
	All data were extracted independently by two investigators on to a Microsoft Excel spreadsheet (XP professional edition; Microsoft Corp, Redmond, WA, USA) as dichotomous outcomes (opportunistic infection or no opportunistic infection, malignancy or no malignancy). The following data were also extracted for each trial, where available: number of centres, country of origin, geographical region, disease type (UC or CD) and distribution, dosage and schedule of active therapy, duration of therapy, duration of follow-up, proportion of patients in each arm of the trial receiving concomitant immunosuppressant or glucocorticosteroid therapy, and number of individuals incurring each (or any) of the opportunistic infections or malignancies of interest. For maintenance of remission trials we also recorded whether patients in the placebo arm had been exposed to anti-integrin antibodies in order to induce remission prior to study entry. Data were extracted as intention-to-treat analyses, wherever trial reporting allowed this. 

Assessment of Risk of Bias
	This was performed independently by two investigators, with disagreements resolved by discussion, and was assessed according to methods described in the Cochrane handbook.  HYPERLINK \l "_ENREF_22" \o "Higgins, 2009 #164"  ADDIN EN.CITE <EndNote><Cite><Author>Higgins</Author><Year>2009</Year><RecNum>164</RecNum><DisplayText><style face="superscript">22</style></DisplayText><record><rec-number>164</rec-number><foreign-keys><key app="EN" db-id="wwaffps2axz0tyewa52xw9rofzd5z59xe5rx">164</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Higgins, J. P. T.</author><author>Green, S.</author></authors></contributors><titles><title>Cochrane handbook for systematic reviews of interventions: Version 5.0.2</title><secondary-title>www.cochrane-handbook.org</secondary-title></titles><periodical><full-title>www.cochrane-handbook.org</full-title></periodical><reprint-edition>NOT IN FILE</reprint-edition><dates><year>2009</year></dates><urls></urls></record></Cite></EndNote>22 The method used to generate the randomisation schedule, the method used to conceal allocation, whether blinding was implemented, what proportion of patients had incomplete outcomes data, and whether there was evidence of selective reporting of outcomes were all recorded. Studies were judged as low risk of bias if they were low risk across all these domains.

Data Synthesis and Statistical Analysis
Study data were pooled using a random effects model, to give a more conservative estimate of the likelihood of opportunistic infection or malignancy with non-gut specific or gut specific anti-integrin antibodies, allowing for any heterogeneity between studies.  HYPERLINK \l "_ENREF_23" \o "DerSimonian, 1986 #88"  ADDIN EN.CITE <EndNote><Cite><Author>DerSimonian</Author><Year>1986</Year><RecNum>88</RecNum><DisplayText><style face="superscript">23</style></DisplayText><record><rec-number>88</rec-number><foreign-keys><key app="EN" db-id="wwaffps2axz0tyewa52xw9rofzd5z59xe5rx">88</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>DerSimonian, R.</author><author>Laird, N.</author></authors></contributors><titles><title>Meta-analysis in clinical trials</title><secondary-title>Control Clin Trials</secondary-title></titles><periodical><full-title>Control Clin Trials</full-title></periodical><pages>177-188</pages><volume>7</volume><reprint-edition>NOT IN FILE</reprint-edition><keywords><keyword>Clinical Trial</keyword></keywords><dates><year>1986</year></dates><urls></urls></record></Cite></EndNote>23 Pooled results were expressed as a relative risk (RR) of opportunistic infection or malignancy, with 95% confidence intervals (CI), with non-gut specific or gut specific anti-integrin antibodies compared with placebo. Where a pooled relative risk was statistically significant, we planned to calculate the number needed to harm, with 95% CIs, from the reciprocal of the risk difference from the meta-analysis. 
The results of individual studies can be diverse, and this inconsistency within a single meta-analysis is quantified with a statistical test of heterogeneity, the I2, to assess whether the variation across trials is due to true heterogeneity, or chance. The value of I2 ranges from 0% to 100%, with 0% representing no observed heterogeneity, and larger values indicating increasing heterogeneity. A value ≤25%, accompanied by a P value of >0.10 for the 2 test, was arbitrarily chosen to represent low levels of heterogeneity.  HYPERLINK \l "_ENREF_24" \o "Higgins, 2003 #163"  ADDIN EN.CITE <EndNote><Cite><Author>Higgins</Author><Year>2003</Year><RecNum>163</RecNum><DisplayText><style face="superscript">24</style></DisplayText><record><rec-number>163</rec-number><foreign-keys><key app="EN" db-id="wwaffps2axz0tyewa52xw9rofzd5z59xe5rx">163</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Higgins, J. P. T.</author><author>Thompson, S. G.</author><author>Deeks, J. J.</author><author>Altman, D. G.</author></authors></contributors><titles><title>Measuring inconsistency in meta-analyses</title><secondary-title>Br Med J</secondary-title></titles><periodical><full-title>Br Med J</full-title></periodical><pages>557-560</pages><volume>327</volume><reprint-edition>NOT IN FILE</reprint-edition><dates><year>2003</year></dates><urls><related-urls><url>http://bmj.bmjjournals.com</url></related-urls></urls></record></Cite></EndNote>24
We planned to perform a priori subgroup analyses according to disease type (CD versus UC), duration of therapy (≥52 weeks versus <52 weeks), use of concomitant immunosuppressant or glucocorticosteroid therapy (>5% difference in proportion exposed to either between individual treatment arms), exposure to anti-integrin antibodies during induction of remission, and risk of bias of the trials. We compared the individual RRs between these subgroup analyses using the Cochran Q statistic.






The search strategy identified 1,579 citations, 1,563 of which were excluded after examining the title and abstract. Sixteen articles reporting on the efficacy of anti-integrin antibodies in IBD were retrieved and evaluated in more detail.  ADDIN EN.CITE ,  Four of these were excluded,  ADDIN EN.CITE , , ,  two because there was no placebo arm,  ADDIN EN.CITE ,  and two because only a single infusion was used. ,  Agreement between investigators for trial eligibility was perfect (Kappa statistic = 1.0).
This left 12 articles eligible for inclusion, containing 3007 patients with IBD.  ADDIN EN.CITE , ,  Of these, seven articles studied the efficacy of anti-integrin antibodies in CD, ADDIN EN.CITE , , , , , ,   and five in UC.  ADDIN EN.CITE , , , ,  Duration of follow-up ranged between 6 and 60 weeks. Detailed trial characteristics are provided in Table 1. Only four of the RCTs we identified were judged as being at low risk of bias (Supplementary Table 1).  ADDIN EN.CITE , , , 

Details of Individual Opportunistic Infections




Overall Risk of Opportunistic Infections with Anti-integrin Antibodies Versus Placebo in IBD
	In four trials, 643 were randomised to receive non-gut specific anti-integrin antibodies, and 554 to placebo. In total, there were seven (1.1%) opportunistic infections among patients allocated to non-gut specific anti-integrin antibodies, compared with one (0.2%) in those assigned to placebo. However, the RR of developing an opportunistic infection was not significantly higher with non-gut specific anti-integrin antibodies than with placebo (2.34; 95% CI 0.05 to 108.72) (Figure 2), with statistically significant heterogeneity detected between studies (I2 = 69%, P = 0.07). In eight trials, 1146 patients were randomised to receive gut specific anti-integrin antibodies, and 664 to placebo. There were only two (0.2%) opportunistic infections among those randomised to gut specific anti-integrin antibodies, compared with none among those allocated to placebo (RR = 1.55; 95% CI 0.16 to 14.83), with no significant heterogeneity between studies.  There were too few studies containing the events of interest to reliably assess for evidence of publication bias, or other small study effects. 
We conducted a priori subgroup analyses. These did not reveal any individual trial or patient characteristics that increased the RR of opportunistic infection with non-gut specific or gut specific anti-integrin antibodies. The RR of opportunistic infection was generally higher in trials of non-gut specific anti-integrin antibodies with a duration of therapy of at least 52 weeks (RR = 15.00; 95% CI 0.86 to 261), but remained non-significant. In RCTs of gut specific anti-integrin antibodies, again the RR was not significantly greater (1.50; 95% CI 0.06 to 36.49) (Cochran Q = 1.47, P = 0.22).

Details of Individual Cancers
Individual cancers among patients receiving anti-integrin antibodies included three basal cell carcinomas, one colorectal cancer, and one ependymoma. Among patients receiving placebo there was one basal cell carcinoma, one colorectal carcinoma, and one transitional cell carcinoma (Supplementary Table 2). There were no cases of lymphoma in either of the treatment arms in any of the trials.

Overall Risk of Malignancy with Anti-integrin Antibodies Versus Placebo in IBD
	In total, there were two (0.3%) malignancies among patients allocated to non-gut specific anti-integrin antibodies, compared with one (0.2%) among those assigned to placebo. The RR of malignancy was not significantly different between the treatment and placebo groups (1.57; 95% CI 0.19 to 12.74) (Supplementary Figure 1). There was no statistically significant heterogeneity detected between studies (I2 = 0%, P = 0.62). Among the 1146 patients randomised to gut specific anti-integrin antibodies, there were three (0.3%) malignancies, compared with two (0.3%) among 664 receiving placebo (RR = 0.78; 95% CI 0.15 to 4.02) (Supplementary Figure 1), with no heterogeneity between studies. Again, there were too few studies containing the events of interest to reliably assess for evidence of publication bias, or other small study effects. 




This systematic review and meta-analysis has not detected a significant increase in either opportunistic infections or malignancies with non-gut specific or gut specific anti-integrin antibodies compared with placebo in all available RCTs published to date. Opportunistic infection occurred in 0.2% to 1.1% of those allocated to anti-integrin antibodies, and malignancy in 0.3%. The commonest opportunistic infections observed were herpes zoster and cytomegalovirus infections, occurring in four and two individuals respectively. Subgroup analyses did not reveal any RCT or patient characteristics that increased the likelihood of either of the events of interest, but there was a trend towards a higher RR of opportunistic infection in trials of non-gut specific anti-integrin antibodies with duration of therapy of at least 52 weeks. The failure to detect a significant difference in this subgroup analysis may be due to a combination of relatively short duration of therapy in most trials, and limited power as the events of interest were rare. 
Strengths of this meta-analysis include our use of rigorous and conservative methodologies. These include the reporting of our search strategy, inclusion criteria, and data extraction processes. In addition, two reviewers conducted independent data extraction, with discrepancies checked and resolved. We used an intention-to-treat analysis and pooled data with a random effects model, in order to avoid any overestimation of the risk of opportunistic infections or malignancies with anti-integrin antibodies for the treatment of IBD. In addition, there was no significant heterogeneity detected between studies when data were pooled to estimate the RR of opportunistic infection or malignancy in most of our analyses. 
Limitations of this systematic review and meta-analysis, as with any other study of its type, arise from the characteristics of the published literature we identified. Only four of the RCTs were at low risk of bias, in terms of reporting the method used to generate the randomisation schedule and conceal treatment allocation. However, as the outcomes of interest we studied were not the primary endpoints of these trials, this is unlikely to have affected our results. The pooling of data from trials in both CD and UC, with various durations of therapy, could be criticised. However, the fact that we performed analyses according to site of action, disease under study, and duration of therapy, allowed us to assess the impact of these trial characteristics on the RR of developing opportunistic infection or malignancy. The duration of therapy in nine of the identified RCTs was 12 weeks or less, and the maximum duration was 56 weeks, meaning that time for the events of interest to occur was limited in some trials, and the risk of opportunistic infection or malignancy beyond this time-frame therefore cannot be quantified by this meta-analysis. This is of particular relevance for natalizumab, where the risk of progressive multifocal leukoencephelopathy appears to increase with a longer duration of therapy,  HYPERLINK \l "_ENREF_38" \o "Bloomgren, 2012 #511"  ADDIN EN.CITE <EndNote><Cite><Author>Bloomgren</Author><Year>2012</Year><RecNum>511</RecNum><DisplayText><style face="superscript">38</style></DisplayText><record><rec-number>511</rec-number><foreign-keys><key app="EN" db-id="wwaffps2axz0tyewa52xw9rofzd5z59xe5rx">511</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Bloomgren, G.</author><author>Richman, S.</author><author>Hotermans, C.</author><author>Subramanyam, M.</author><author>Goelz, S.</author><author>Natarajan, A.</author><author>Lee, S.</author><author>Plavina, T.</author><author>Scanlon, J. V.</author><author>Sandrock, A.</author><author>Bozic, C.</author></authors></contributors><titles><title>Risk of natalizumab-associated progressive multifocal leukoencephalopathy</title><secondary-title>N Engl J Med</secondary-title></titles><periodical><full-title>N Engl J Med</full-title></periodical><pages>1870-80</pages><volume>366</volume><number>20</number><dates><year>2012</year></dates><isbn>1533-4406 (Electronic)&#xD;0028-4793 (Linking)</isbn><urls></urls></record></Cite></EndNote>38 but only one of the trials we identified provided data beyond 12 weeks. Finally, as time to the development of infection or malignancy was not available in any of the RCTs, whether the risk of these events remains uniform during extended therapy is unclear.
In trials where rates of concomitant immunosuppressant therapy or glucocorticosteroid use were higher among patients allocated to anti-integrin antibodies, the RR of opportunistic infection or malignancy may have been overestimated. Unfortunately, in three of the RCTs we identified, these data were either not reported, or were not extractable. When we included only trials with a ≤5% difference in the proportion of patients receiving either concomitant immunosuppressants or glucocorticosteroids in each arm the pooled RR of opportunistic infection, but not malignancy, decreased but there was still no statistically significant difference compared with the placebo arm. 
We also cannot exclude the fact that, because some patients who received placebo in the randomised part of the studies we identified were exposed to anti-integrin antibodies as open-label treatment prior to randomisation in to the study itself, this has led to an increase in opportunistic infections or malignancies in the placebo arm, and therefore an underestimation of the true RR of these sequelae with anti-integrin antibodies. However, this would appear unlikely, given how rare these events were, and our subgroup analysis excluding studies that included these patients from the analysis demonstrated no statistically significant increase in the pooled RR for either opportunistic infection or malignancy. 
	There have been several previous systematic reviews and meta-analyses conducted examining the efficacy and safety of anti-integrin antibodies in IBD, one of which reported an increased risk of serious adverse events and nasopharyngitis with vedolizumab.  HYPERLINK \l "_ENREF_39" \o "Wang, 2014 #510"  ADDIN EN.CITE <EndNote><Cite><Author>Wang</Author><Year>2014</Year><RecNum>510</RecNum><DisplayText><style face="superscript">39</style></DisplayText><record><rec-number>510</rec-number><foreign-keys><key app="EN" db-id="wwaffps2axz0tyewa52xw9rofzd5z59xe5rx">510</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Wang, M. C.</author><author>Zhang, L. Y.</author><author>Han, W.</author><author>Shao, Y.</author><author>Chen, M.</author><author>Ni, R.</author><author>Wang, G. N.</author><author>Wei, F. X.</author><author>Zhang, Y. W.</author><author>Xu, X. D.</author><author>Zhang, Y. C.</author></authors></contributors><titles><title>PRISMA--efficacy and safety of vedolizumab for inflammatory bowel diseases: a systematic review and meta-analysis of randomized controlled trials</title><secondary-title>Medicine</secondary-title></titles><periodical><full-title>Medicine</full-title></periodical><pages>0000000000000326</pages><volume>93</volume><number>28</number><dates><year>2014</year></dates><isbn>1536-5964 (Electronic)&#xD;0025-7974 (Linking)</isbn><work-type>Research Support, Non-U S Gov&apos;t</work-type><urls></urls></record></Cite></EndNote>39 However, to date, no single study has assembled data from all RCTs to assess the risk of opportunistic infection or malignancy. Due to their rarity in clinical trials, until now estimates of the risk of these events occurring with anti-integrin antibodies has relied on case reports and case series, mainly from the neurology literature.  ADDIN EN.CITE 40-44 Our study has shown that the risk of such an event occurring in a treated patient is between 0.2% and 1.1%, and this should be balanced against the efficacy of these agents for patients with IBD, as well as the risk that patients are prepared to accept in exchange for remission of their symptoms, which may be quite different to that anticipated by clinicians.  HYPERLINK \l "_ENREF_45" \o "Johnson, 2007 #498"  ADDIN EN.CITE <EndNote><Cite><Author>Johnson</Author><Year>2007</Year><RecNum>498</RecNum><DisplayText><style face="superscript">45</style></DisplayText><record><rec-number>498</rec-number><foreign-keys><key app="EN" db-id="wwaffps2axz0tyewa52xw9rofzd5z59xe5rx">498</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Johnson, F. R.</author><author>Ozdemir, S.</author><author>Mansfield, C.</author><author>Hass, S.</author><author>Miller, D. W.</author><author>Siegel, C. A.</author><author>Sands, B. E.</author></authors></contributors><titles><title>Crohn&apos;s disease patients&apos; risk-benefit preferences: serious adverse event risks versus treatment efficacy</title><secondary-title>Gastroenterology</secondary-title></titles><periodical><full-title>Gastroenterology</full-title></periodical><pages>769-79</pages><volume>133</volume><number>3</number><dates><year>2007</year></dates><isbn>0016-5085 (Print)&#xD;0016-5085 (Linking)</isbn><work-type>Research Support, Non-U S Gov&apos;t</work-type><urls></urls></record></Cite></EndNote>45 Although our study gives an estimate of the risk of experiencing either opportunistic infection or malignancy with anti-integrin antibodies, and is not subject to the inherent biases associated with non-randomised studies, it should be remembered that patients encountered in normal clinical practice differ substantially from participants in RCTs. Our data should therefore be used to inform decision-making on a case-by-case basis only, and provide support for current guidelines for the prevention, diagnosis, and management of opportunistic infection from the European Crohn’s and Colitis Organisation.  HYPERLINK \l "_ENREF_46" \o "Rahier, 2009 #311"  ADDIN EN.CITE <EndNote><Cite><Author>Rahier</Author><Year>2009</Year><RecNum>311</RecNum><DisplayText><style face="superscript">46</style></DisplayText><record><rec-number>311</rec-number><foreign-keys><key app="EN" db-id="wwaffps2axz0tyewa52xw9rofzd5z59xe5rx">311</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Rahier, J. F.</author><author>Ben-Horin, S.</author><author>Chowers, Y.</author><author>Conlon, C.</author><author>De Munter, P.</author><author>D&apos;Haens, G.</author><author>Domenech, E.</author><author>Eliakim, R.</author><author>Eser, A.</author><author>Frater, J.</author><author>Gassull, M.</author><author>Giladi, M.</author><author>Kaser, A.</author><author>Lemann, M.</author><author>Moreels, T.</author><author>Moschen, A.</author><author>Pollok, R.</author><author>Reinisch, W.</author><author>Schunter, M.</author><author>Stange, E. F.</author><author>Tilg, H.</author><author>van Assche, G.</author><author>Viget, N.</author><author>Vucelic, B.</author><author>Walsh, A.</author><author>Weiss, G.</author><author>Yazdanpanah, Y.</author><author>Zabana, Y.</author><author>Travis, S. P.</author><author>Colombel, J. F.</author><author>European, Crohn&apos;s</author><author>Colitis, Organisation</author></authors></contributors><titles><title>European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease</title><secondary-title>J Crohns Colitis</secondary-title></titles><periodical><full-title>J Crohns Colitis</full-title></periodical><pages>47-91</pages><volume>3</volume><reprint-edition>IN FILE</reprint-edition><dates><year>2009</year></dates><urls></urls></record></Cite></EndNote>46 
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Box 1. Eligibility criteria.

Randomised controlled trials.
Adults (>90% of patients aged >16 years) with inflammatory bowel disease.
Compared anti-integrin antibodies * with placebo.
Minimum duration of therapy of 2 weeks.
Opportunistic infections† or malignancies during randomised double-blind treatment period reported in both arms of the trial.

* Natalizumab, vedolizumab, or etrolizumab.
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Table 1. Characteristics of Randomised Controlled Trials of Anti-integrin Antibodies Versus Placebo in IBD.
Study	Country, and number of centres	Number of patients and disease under study (distribution)	Dosage and schedule of anti-integrin antibody used (duration of therapy)	Duration of follow-up
Ghosh 2003  HYPERLINK \l "_ENREF_14" \o "Ghosh, 2003 #128"  ADDIN EN.CITE <EndNote><Cite><Author>Ghosh</Author><Year>2003</Year><RecNum>128</RecNum><DisplayText><style face="superscript">14</style></DisplayText><record><rec-number>128</rec-number><foreign-keys><key app="EN" db-id="wwaffps2axz0tyewa52xw9rofzd5z59xe5rx">128</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Ghosh, S.</author><author>Goldin, E.</author><author>Gordon, F. H.</author><author>Malchow, H. A.</author><author>Rask-Madsen, J.</author><author>Rutgeerts, P.</author><author>Vyhnalek, P.</author><author>Zadorova, Z.</author><author>Palmer, T.</author><author>Donoghue, S.</author><author>for the Natalizumab Pan-European Study, Group</author></authors></contributors><titles><title>Natalizumab for active Crohn&apos;s disease</title><secondary-title>N Engl J Med</secondary-title></titles><periodical><full-title>N Engl J Med</full-title></periodical><pages>24-32</pages><volume>348</volume><reprint-edition>NOT IN FILE</reprint-edition><dates><year>2003</year></dates><urls></urls></record></Cite></EndNote>14	Multi-national, 35 sites	180 patients with luminal CD (24% ileal, 52% ileocolonic, 24% colonic)	Natalizumab 3mg/kg at weeks 0 and 4, or 6mg/kg at weeks 0 and 4 (4 weeks)	12 weeks
Feagan 2005  HYPERLINK \l "_ENREF_15" \o "Feagan, 2005 #486"  ADDIN EN.CITE <EndNote><Cite><Author>Feagan</Author><Year>2005</Year><RecNum>486</RecNum><DisplayText><style face="superscript">15</style></DisplayText><record><rec-number>486</rec-number><foreign-keys><key app="EN" db-id="wwaffps2axz0tyewa52xw9rofzd5z59xe5rx">486</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Feagan, B. G.</author><author>Greenberg, G. R.</author><author>Wild, G.</author><author>Fedorak, R. N.</author><author>Pare, P.</author><author>McDonald, J. W.</author><author>Dube, R.</author><author>Cohen, A.</author><author>Steinhart, A. H.</author><author>Landau, S.</author><author>Aguzzi, R. A.</author><author>Fox, I. H.</author><author>Vandervoort, M. K.</author></authors></contributors><titles><title>Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin</title><secondary-title>N Engl J Med</secondary-title></titles><periodical><full-title>N Engl J Med</full-title></periodical><pages>2499-507</pages><volume>352</volume><dates><year>2005</year></dates><isbn>1533-4406 (Electronic)&#xD;0028-4793 (Linking)</isbn><work-type>Clinical Trial&#xD;Multicenter Study&#xD;Randomized Controlled Trial&#xD;Research Support, N I H , Extramural&#xD;Research Support, Non-U S Gov&apos;t&#xD;Research Support, U S Gov&apos;t, P H S</work-type><urls></urls></record></Cite></EndNote>15	Canada, 20 sites	181 patients with UC (not reported)	Vedolizumab 0.5 or 2mg/kg on day 1 and 29 (4 weeks)	6 weeks
Sandborn 2005 ENACT-2  HYPERLINK \l "_ENREF_17" \o "Sandborn, 2005 #346"  ADDIN EN.CITE <EndNote><Cite><Author>Sandborn</Author><Year>2005</Year><RecNum>346</RecNum><DisplayText><style face="superscript">17</style></DisplayText><record><rec-number>346</rec-number><foreign-keys><key app="EN" db-id="wwaffps2axz0tyewa52xw9rofzd5z59xe5rx">346</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Sandborn, W. J.</author><author>Colombel, J. F.</author><author>Enns, R.</author><author>Feagan, B. G.</author><author>Hanauer, S. B.</author><author>Lawrance, I. C.</author><author>Panaccione, R.</author><author>Sanders, M.</author><author>Schreiber, S.</author><author>Targan, S. R.</author><author>van Deventer, S. J. H.</author><author>Goldblum, R.</author><author>Despain, D.</author><author>Hogge, G. S.</author><author>Rutgeerts, P.</author><author>for the International Efficacy of Natalizumab as Active Crohn&apos;s, Therapy</author><author>the Evaluation of Natalizumab as Continuous Therapy Trial, Groups</author></authors></contributors><titles><title>Natalizumab induction and maintenance therapy for Crohn&apos;s disease</title><secondary-title>N Engl J Med</secondary-title></titles><periodical><full-title>N Engl J Med</full-title></periodical><pages>1912-1925</pages><volume>353</volume><reprint-edition>NOT IN FILE</reprint-edition><dates><year>2005</year></dates><urls></urls></record></Cite></EndNote>17	Multi-national, 142 sites	428 patients with luminal CD (not reported)	Natalizumab 300mg at weeks 0, 4, and 8, then 4-weekly thereafter (56 weeks)	60 weeks
Sands 2007  HYPERLINK \l "_ENREF_35" \o "Sands, 2007 #360"  ADDIN EN.CITE <EndNote><Cite><Author>Sands</Author><Year>2007</Year><RecNum>360</RecNum><DisplayText><style face="superscript">35</style></DisplayText><record><rec-number>360</rec-number><foreign-keys><key app="EN" db-id="wwaffps2axz0tyewa52xw9rofzd5z59xe5rx">360</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Sands, B. E.</author><author>Kozarek, R.</author><author>Spainhour, J.</author><author>Barish, C. F.</author><author>Becker, S.</author><author>Goldberg, L.</author><author>Katz, S.</author><author>Goldblum, R.</author><author>Harrigan, R.</author><author>Hilton, D.</author><author>Hanauer, S. B.</author></authors></contributors><titles><title>Safety and tolerability of concurrent natalizumab treatment for patients with Crohn&apos;s disease not in remission while receiving infliximab</title><secondary-title>Inflamm Bowel Dis</secondary-title></titles><periodical><full-title>Inflamm Bowel Dis</full-title></periodical><pages>2-11</pages><volume>13</volume><reprint-edition>NOT IN FILE</reprint-edition><dates><year>2007</year></dates><urls></urls></record></Cite></EndNote>35	USA, 17 sites	79 patients with luminal CD (19% ileal, 54% ileocolonic, 26% colonic)	Natalizumab 300mg at weeks 0, 4, and 8 (8 weeks)	10 weeks
Targan 2007 ENCORE  HYPERLINK \l "_ENREF_34" \o "Targan, 2007 #405"  ADDIN EN.CITE <EndNote><Cite><Author>Targan</Author><Year>2007</Year><RecNum>405</RecNum><DisplayText><style face="superscript">34</style></DisplayText><record><rec-number>405</rec-number><foreign-keys><key app="EN" db-id="wwaffps2axz0tyewa52xw9rofzd5z59xe5rx">405</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Targan, S. R.</author><author>Feagan, B. G.</author><author>Fedorak, R. N.</author><author>Lashner, B.</author><author>Panaccione, R.</author><author>Present, D. H.</author><author>Spehlmann, M. E.</author><author>Rutgeerts, P. J.</author><author>Tulassay, Z.</author><author>Volfova, M.</author><author>Wolf, D. C.</author><author>Hernandez, C.</author><author>Bornstein, J.</author><author>Sandborn, W. J.</author></authors></contributors><titles><title>Natalizumab for the treatment of active Crohn&apos;s disease: results of the ENCORE trial</title><secondary-title>Gastroenterology</secondary-title></titles><periodical><full-title>Gastroenterology</full-title></periodical><pages>1672-1683</pages><volume>132</volume><reprint-edition>NOT IN FILE</reprint-edition><dates><year>2007</year></dates><urls></urls></record></Cite></EndNote>34	Multi-national, 114 sites	510 patients with luminal CD (24% ileal, 50% ileocolonic, 26% colonic)	Natalizumab 300mg at weeks 0, 4, and 8 (8 weeks)	12 weeks
Feagan 2008  HYPERLINK \l "_ENREF_27" \o "Feagan, 2008 #482"  ADDIN EN.CITE <EndNote><Cite><Author>Feagan</Author><Year>2008</Year><RecNum>482</RecNum><DisplayText><style face="superscript">27</style></DisplayText><record><rec-number>482</rec-number><foreign-keys><key app="EN" db-id="wwaffps2axz0tyewa52xw9rofzd5z59xe5rx">482</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Feagan, B. G.</author><author>Greenberg, G. R.</author><author>Wild, G.</author><author>Fedorak, R. N.</author><author>Pare, P.</author><author>McDonald, J. W.</author><author>Cohen, A.</author><author>Bitton, A.</author><author>Baker, J.</author><author>Dube, R.</author><author>Landau, S. B.</author><author>Vandervoort, M. K.</author><author>Parikh, A.</author></authors></contributors><titles><title>Treatment of active Crohn&apos;s disease with MLN0002, a humanized antibody to the alpha4beta7 integrin</title><secondary-title>Clin Gastroenterol Hepatol</secondary-title></titles><periodical><full-title>Clin Gastroenterol Hepatol</full-title></periodical><pages>1370-7</pages><volume>6</volume><dates><year>2008</year></dates><isbn>1542-7714 (Electronic)&#xD;1542-3565 (Linking)</isbn><work-type>Randomized Controlled Trial&#xD;Research Support, Non-U S Gov&apos;t</work-type><urls></urls></record></Cite></EndNote>27	Canada, 21 sites 	185 patients with luminal CD (not reported)	Vedolizumab 0.5 or 2mg/kg on day 1 and 29 (4 weeks)	26 weeks
Parikh 2012  HYPERLINK \l "_ENREF_28" \o "Parikh, 2012 #484"  ADDIN EN.CITE <EndNote><Cite><Author>Parikh</Author><Year>2012</Year><RecNum>484</RecNum><DisplayText><style face="superscript">28</style></DisplayText><record><rec-number>484</rec-number><foreign-keys><key app="EN" db-id="wwaffps2axz0tyewa52xw9rofzd5z59xe5rx">484</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Parikh, A.</author><author>Leach, T.</author><author>Wyant, T.</author><author>Scholz, C.</author><author>Sankoh, S.</author><author>Mould, D. R.</author><author>Ponich, T.</author><author>Fox, I.</author><author>Feagan, B. G.</author></authors></contributors><titles><title>Vedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging study</title><secondary-title>Inflamm Bowel Dis</secondary-title></titles><periodical><full-title>Inflamm Bowel Dis</full-title></periodical><pages>1470-9</pages><volume>18</volume><dates><year>2012</year></dates><isbn>1536-4844 (Electronic)&#xD;1078-0998 (Linking)</isbn><work-type>Clinical Trial, Phase II&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U S Gov&apos;t</work-type><urls></urls></record></Cite></EndNote>28	Canada and Russia, 11 sites	47 patients with UC (not reported)	Vedolizumab 2, 6, or 10 mg/kg on day 1, 15, 29, and 85  (12 weeks)	36 weeks
Feagan 2013 GEMINI-1  HYPERLINK \l "_ENREF_16" \o "Feagan, 2013 #483"  ADDIN EN.CITE <EndNote><Cite><Author>Feagan</Author><Year>2013</Year><RecNum>483</RecNum><DisplayText><style face="superscript">16</style></DisplayText><record><rec-number>483</rec-number><foreign-keys><key app="EN" db-id="wwaffps2axz0tyewa52xw9rofzd5z59xe5rx">483</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Feagan, B. G.</author><author>Rutgeerts, P.</author><author>Sands, B. E.</author><author>Hanauer, S.</author><author>Colombel, J. F.</author><author>Sandborn, W. J.</author><author>Van Assche, G.</author><author>Axler, J.</author><author>Kim, H. J.</author><author>Danese, S.</author><author>Fox, I.</author><author>Milch, C.</author><author>Sankoh, S.</author><author>Wyant, T.</author><author>Xu, J.</author><author>Parikh, A.</author></authors></contributors><titles><title>Vedolizumab as induction and maintenance therapy for ulcerative colitis</title><secondary-title>N Engl J Med</secondary-title></titles><periodical><full-title>N Engl J Med</full-title></periodical><pages>699-710</pages><volume>369</volume><dates><year>2013</year></dates><isbn>1533-4406 (Electronic)&#xD;0028-4793 (Linking)</isbn><work-type>Clinical Trial, Phase III&#xD;Multicenter Study&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U S Gov&apos;t</work-type><urls></urls></record></Cite></EndNote>16	Multi-national, 211 sites	373 patients with UC (11% proctosigmoiditis, 40% left-sided, 50% extensive)	Vedolizumab 300mg every 4 or 8 weeks (52 weeks)	52 weeks
Rutgeerts 2013  HYPERLINK \l "_ENREF_33" \o "Rutgeerts, 2013 #490"  ADDIN EN.CITE <EndNote><Cite><Author>Rutgeerts</Author><Year>2013</Year><RecNum>490</RecNum><DisplayText><style face="superscript">33</style></DisplayText><record><rec-number>490</rec-number><foreign-keys><key app="EN" db-id="wwaffps2axz0tyewa52xw9rofzd5z59xe5rx">490</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Rutgeerts, P. J.</author><author>Fedorak, R. N.</author><author>Hommes, D. W.</author><author>Sturm, A.</author><author>Baumgart, D. C.</author><author>Bressler, B.</author><author>Schreiber, S.</author><author>Mansfield, J. C.</author><author>Williams, M.</author><author>Tang, M.</author><author>Visich, J.</author><author>Wei, X.</author><author>Keir, M.</author><author>Luca, D.</author><author>Danilenko, D.</author><author>Egen, J.</author><author>O&apos;Byrne, S.</author></authors></contributors><titles><title>A randomised phase I study of etrolizumab (rhuMAb beta7) in moderate to severe ulcerative colitis</title><secondary-title>Gut</secondary-title></titles><periodical><full-title>Gut</full-title></periodical><pages>1122-30</pages><volume>62</volume><dates><year>2013</year></dates><isbn>1468-3288 (Electronic)&#xD;0017-5749 (Linking)</isbn><work-type>Clinical Trial, Phase I&#xD;Multicenter Study&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U S Gov&apos;t</work-type><urls></urls></record></Cite></EndNote>33	Multi-national, 15 sites	23 patients with UC (not reported)	Etrolizumab 0.5, 1.5, 3, or 4mg/kg at weeks 0, 4, and 8 (8 weeks)	28 weeks
Sandborn 2013 GEMINI-2  HYPERLINK \l "_ENREF_18" \o "Sandborn, 2013 #357"  ADDIN EN.CITE <EndNote><Cite><Author>Sandborn</Author><Year>2013</Year><RecNum>357</RecNum><DisplayText><style face="superscript">18</style></DisplayText><record><rec-number>357</rec-number><foreign-keys><key app="EN" db-id="wwaffps2axz0tyewa52xw9rofzd5z59xe5rx">357</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Sandborn, W. J.</author><author>Feagan, B. G.</author><author>Rutgeerts, P.</author><author>Hanauer, S.</author><author>Colombel, J. F.</author><author>Sands, B. E.</author><author>Lukas, M.</author><author>Fedorak, R. N.</author><author>Lee, S.</author><author>Bressler, B.</author><author>Fox, I.</author><author>Rosario, M.</author><author>Sankoh, S.</author><author>Xu, J.</author><author>Stephens, K.</author><author>Milch, C.</author><author>Parikh, A.</author><author>Gemini Study Group</author></authors></contributors><titles><title>Vedolizumab as induction and maintenance therapy for Crohn&apos;s disease</title><secondary-title>N Engl J Med</secondary-title></titles><periodical><full-title>N Engl J Med</full-title></periodical><pages>711-721</pages><volume>369</volume><reprint-edition>IN FILE</reprint-edition><dates><year>2013</year></dates><urls></urls></record></Cite></EndNote>18	Multi-national, 285 sites	461 patients with luminal CD (18% ileal, 57% ileocolonic, 25% colonic)	Vedolizumab 300mg every 4 or 8 weeks (52 weeks)	52 weeks
Sands 2014 GEMINI-3  HYPERLINK \l "_ENREF_29" \o "Sands, 2014 #485"  ADDIN EN.CITE <EndNote><Cite><Author>Sands</Author><Year>2014</Year><RecNum>485</RecNum><DisplayText><style face="superscript">29</style></DisplayText><record><rec-number>485</rec-number><foreign-keys><key app="EN" db-id="wwaffps2axz0tyewa52xw9rofzd5z59xe5rx">485</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Sands, B. E.</author><author>Feagan, B. G.</author><author>Rutgeerts, P.</author><author>Colombel, J. F.</author><author>Sandborn, W. J.</author><author>Sy, R.</author><author>D&apos;Haens, G.</author><author>Ben-Horin, S.</author><author>Xu, J.</author><author>Rosario, M.</author><author>Fox, I.</author><author>Parikh, A.</author><author>Milch, C.</author><author>Hanauer, S.</author></authors></contributors><titles><title>Effects of vedolizumab induction therapy for patients with Crohn&apos;s disease in whom tumor necrosis factor antagonist treatment failed</title><secondary-title>Gastroenterology</secondary-title></titles><periodical><full-title>Gastroenterology</full-title></periodical><pages>618-627</pages><volume>147</volume><dates><year>2014</year></dates><isbn>1528-0012 (Electronic)&#xD;0016-5085 (Linking)</isbn><work-type>Clinical Trial, Phase III&#xD;Multicenter Study&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U S Gov&apos;t&#xD;Video-Audio Media&#xD;Webcasts</work-type><urls></urls></record></Cite></EndNote>29	Multi-national, 107 sites	416 patients with luminal CD (15% ileal, 61% ileocolonic, 24% colonic)	Vedolizumab 300mg at weeks 0, 4, and 6 (6 weeks)	10 weeks




Table 2. Opportunistic Infections with Anti-integrin Antibodies Versus Placebo in IBD.
	Non-gut specific anti-integrin antibodies (four trials)	Gut specific anti-integrin antibodies (eight trials)
Opportunistic infection	Total number of anti-integrin antibody patients	Number of anti-integrin antibody patients experiencing opportunistic infection (%)	Total number of placebo patients 	Number of placebo patients experiencing opportunistic infection (%)	Total number of anti-integrin antibody patients	Number of anti-integrin antibody patients experiencing opportunistic infection (%)	Total number of placebo patients 	Number of placebo patients experiencing opportunistic infection (%)
Herpes zoster	643	4 (0.6)	554	0 (0)	1146	0 (0)	664	0 (0)
Cytomegalovirus	643	1 (0.2)	554	0 (0)	1146	1 (0.09)	664	0 (0)
JC virus	643	1 (0.2)	554	0 (0)	1146	0 (0)	664	0 (0)
Mycobacterium tuberculosis	643	0 (0)	554	0 (0)	1146	1 (0.09)	664	0 (0)
Varicella-zoster	643	1 (0.2)	554	0 (0)	1146	0 (0)	664	0 (0)
Herpes simplex	643	0 (0)	554	1 (0.2)	1146	0 (0)	664	0 (0)
Total number	643	7 (1.1)	554	1 (0.2)	1146	2 (0.2)	664	0 (0)


Studies identified in literature search (n = 1,579)

Excluded (title and abstract revealed not appropriate) (n = 1,563)

Studies retrieved for evaluation (n = 16)

Excluded (n = 4) because:
	No placebo arm = 2
	Single infusion of anti-integrin antibody = 2
	
12 articles studying anti-integrin antibodies in IBD:
	CD = 7 RCTs
	UC = 5 RCTs



